UZ Leuven Gasthuisberg

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Amyloidosis1 trial
• Asthma1 trial
• Bladder cancer1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Kidney cancer1 trial
• Melanoma1 trial
• and 7 more

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed9 trials
• Active, not recruiting4 trials
• Recruiting3 trials
• Withdrawn1 trial

Lead sponsor

• Hoffmann-La Roche8 trials
• Universitaire Ziekenhuizen KU Leuven2 trials
• Actuate Therapeutics Inc.1 trial
• AstraZeneca1 trial
• Biotronik AG1 trial
• and 4 more

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study on the Clinical Efficacy of Teclistamab and Talquetamab

  NCT06477783· Universitaire Ziekenhuizen KU Leuven· Source

  Contact: Stéphanie Bézy

• Active, not recruiting

  First in Men Study: BIOMAG-I

  NCT04157153· Biotronik AG· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source

• Active, not recruiting

  Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

  NCT03616886· Phase 1/2· Jules Bordet Institute· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Withdrawn

  BE.Amycon Registry UZ Leuven

  NCT06998355· Universitaire Ziekenhuizen KU Leuven· Source

• Completed

  The Effect of a Cold Air Eucapnic Hyperventilation Test on Lower Respiratory Airways in Healthy Volunteers and Patients With Asthma

  NCT07220928· KU Leuven· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  Post Market Clinical Follow-up Study for the Pamira ICD Lead Family

  NCT05621187· Biotronik SE & Co. KG· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

  NCT02913482· Phase 2· Hoffmann-La Roche· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source